Active, not recruitingPHASE1, PHASE2NCT01499888

Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)

Studying Genetic hemoglobinopathy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Illinois at Chicago
Principal Investigator
Damiano Rondelli, MD, MD
University of Illinois at Chicago
Intervention
Allogeneic Non-Myeloablative Stem Cell Transplantation(procedure)
Enrollment
45 enrolled
Eligibility
16-60 years · All sexes
Timeline
20112029

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01499888 on ClinicalTrials.gov

Other trials for Genetic hemoglobinopathy

Additional recruiting or active studies for the same condition.

See all trials for Genetic hemoglobinopathy

← Back to all trials